Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, bringing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 into J&J’s oncology portfolio. The deal follows phase I/II data showing PSA reductions and tumor responses in metastatic castration‑resistant prostate cancer (mCRPC). J&J said it will accelerate the ongoing study and fold the RIPTAC modality into its R&D plans. Halda’s RIPTACs are bifunctional small molecules that bind a tumor‑specific protein and an essential survival protein to induce targeted cell death — a modality designed to circumvent common resistance mechanisms. The companies noted generally manageable safety in early cohorts and selected dose levels for expansion. Analysts and partners cited the data as the primary driver of the transaction and expect J&J to advance registrational planning. This acquisition consolidates an emerging class of targeted small‑molecule degraders and proximity modalities into a major pharma’s pipeline, and J&J’s R&D leadership signaled intent to scale the program quickly. The companies did not disclose detailed timelines for registrational trials beyond accelerating dose expansion and development.